Toggle Main Menu Toggle Search

Open Access padlockePrints

Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention

Lookup NU author(s): Dr Alan Bagnall

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Copyright © 2026 Massachusetts Medical Society. BACKGROUND: Complex percutaneous coronary intervention (PCI) in patients with severely impaired left ventricular function carries a high risk of death and complications. Whether percutaneous left ventricular unloading improves outcomes remains unclear. METHODS: We randomly assigned 300 patients with severe left ventricular dysfunction and extensive coronary artery disease in a 1:1 ratio to a strategy of elective unloading with a microaxial flow pump or to standard care during planned complex PCI. The primary outcome was a hierarchical composite that included death from any cause, disabling stroke, spontaneous myocardial infarction, hospitalization for cardiovascular causes, or periprocedural myocardial injury at a minimum of 12 months, as analyzed according to a win ratio. RESULTS: A total of 148 patients were assigned to receive a microaxial flow pump and 152 to receive standard care. At a median of 22 months (interquartile range, 16 to 30), 36.6% of pairwise comparisons favored the microaxial flow pump, and 43.0% favored standard care (win ratio, 0.85; 95% confidence interval [CI], 0.63 to 1.15; difference, -6.4 percentage points; P = 0.30). Death from any cause occurred in 47 patients in the microaxial-flow-pump group and 33 in the standard-care group (hazard ratio, 1.54; 95% CI, 0.99 to 2.41). There was no material between-group difference in the risk of bleeding or vascular complications. CONCLUSIONS: Among patients with severely impaired left ventricular function undergoing complex PCI, elective left ventricular unloading with a microaxial flow pump did not reduce the risk of major adverse clinical outcomes at a minimum of 12 months. (Funded by the U.K. National Institute for Health and Care Research; CHIP-BCIS3 ClinicalTrials.gov number, NCT05003817.).


Publication metadata

Author(s): Perera D, Ryan M, Ezad SM, Khan SQ, Webb I, O'Kane PD, Weerackody R, Dodd M, Kwok M, Laidlaw L, Van Dyck L, Wrigley B, Strange JW, Bagnall A, Fath-Ordoubadi F, Panoulas VF, Ladwiniec A, Davies JR, Chase A, Owens CG, Watkins S, Rahman H, Pareek N, Rathod K, Rawlins J, Evans R, Hoole SP, Stables RH, Curzen N, Clayton T

Publication type: Article

Publication status: Published

Journal: New England Journal of Medicine

Year: 2026

Volume: 394

Issue: 18

Pages: 1779-1789

Print publication date: 07/05/2026

Online publication date: 29/03/2026

Acceptance date: 02/04/2018

ISSN (print): 0028-4793

ISSN (electronic): 1533-4406

Publisher: Massachusetts Medical Society

URL: https://doi.org/10.1056/NEJMoa2515704

DOI: 10.1056/NEJMoa2515704

PubMed id: 41910380


Altmetrics

Altmetrics provided by Altmetric


Share